Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating

Vaxcyte Inc. (NASDAQ:PCVX) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Vaxcyte Inc. (NASDAQ:PCVX) closed its public offering of the sale of 12.65 million shares of the company’s common stock at $50 per share, raising $632.5 million in gross proceeds in the process. The offering included the full exercise of the underwriters’ option to purchase an additional 1.65 million shares at the public offering price, less underwriting discounts and commissions.

Meanwhile, on January 23, Cantor Fitzgerald reiterated its Overweight rating on Vaxcyte Inc. (NASDAQ:PCVX), noting that the company’s clinical pipeline is progressing according to schedule. The analyst projected that the topline readout from Vaxcyte’s Phase 3 OPUS-1 non-inferiority trial is expected in the fourth quarter of 2026, with an adult Biologics License Application filing planned for 2027. The firm also projected the release of results for the company’s OPUS-2 and OPUS-3 studies to be released in the first half of 2027.

Vaxcyte Inc. (NASDAQ:PCVX) develops vaccines for infectious diseases, focusing on conjugate and protein-based vaccines delivered through a platform based on cell-free protein synthesis technology.

While we acknowledge the potential of PCVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the